“From 2019 to 2024, the percentage of adult patients with a diagnosis of overweight or obesity increased 50.7 percent, and ...

The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

She recommends women undergo a “baseline” dual-energy X-ray absorptiometry (DEXA) scan in their early to mid-30s to help ...

Ozempic and drugs like it have done wonders for weight loss by mimicking the natural hormone GLP-1 ( glucagon-like peptide-1 ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...

Dr Debra Marcos offers expert insight on why GLP-1 medications like Wegovy and Mounjaro are not only transforming the weight ...

Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that ...

Many Mounjaro users are looking into alternative medications following news of a 170 percent price increase in the UK ...

Loss Drug to Irreversible Blindness A growing wave of lawsuits is targeting Novo Nordisk, the manufacturer of the widely used ...